‘Don’t Miss the Next Bull Market’: Billionaire Ken Fisher Heavily Invested in These 2 ‘Strong Buy’ Stocks

After the bearish market of 2022, the markets staged a recovery in 2023, with both the S&P 500 and the NASDAQ in particular showing healthy year-to-date gains. Therefore, it may be a natural tendency for investors who have suffered huge losses to be eyeing the exit door now that the market is re-balancing and the initial investment is back to break even. Is. However, veteran investor Ken Fisher says that this type of thinking is a big mistake.

“As early bull market rallies build, investors – raw from prior declines – sell. It sounds smart,” says Fischer. But it’s the wrong move.

According to Fisher, there are too many bears roaming Wall Street right now, the pendulum has already swung the other way and we are in the early innings of a bull market. The key, now, is to stay in the game. “While many people will suffer breakevenitis, you can avoid it — by keeping long-term goals in mind,” says the billionaire.

Griffin is staying fully invested by putting his money where his mouth is. We dug up the TipRanks database to see what the Street’s stock experts make of a pair of equities that form part of their portfolios. They seem to agree that these are good choices; Both are rated ‘Strong Buy’ by analyst consensus. Let’s take a look at why they’re worth bowing down to right now.

thermo fisher (tmo,

The first Griffin-backed name we’ll look at is a giant in its field. With a market capitalization of over $203 billion, Thermo Fisher is one of the world’s leading healthcare suppliers. The company provides a broad range of scientific solutions including analytical instruments, consumables, reagents, software and services. It caters to a diverse customer base that includes pharmaceutical and biotech companies, academic and research institutions, hospitals and clinical diagnostic laboratories, as well as government agencies.

Despite being a major global concern, TMO is not immune to the changes taking place around it. The company’s recent Q1 report reflected the impact of COVID-19, with testing revenue falling to $140 million from $1.7 billion in the same period a year ago. As a result, revenue fell 9.4% year-over-year to $10.71 billion, though it was $40 million above the Street’s forecast. On the other hand, adjusted EPS of $5.03 met analysts’ expectations. TMO also maintained its guidance for 2023, expecting revenue of $45.3 billion and EPS of $23.70.

Fischer is clearly keen on this healthcare giant. He has a large TMO position owning 2,395,840 shares. These are currently worth over $1.26 billion.

It’s a move that would most likely get the approval of Stifel analyst Daniel Arias. Evaluating the Q1 print and outlook, Arias wrote, “We expect the debate on demand risk to continue, but for us TMO is differentiating itself in a way that reflects the company’s strengths (portfolio diversity, execution quality , advertises stock profit opportunities). So while some investors may be inclined to avoid bioprocess-related names (or equipment companies in general) until the temperature in the room cools off, we believe TMO at 20x may be a good fit for those with a somewhat higher risk tolerance. Very attractive for.

These comments underlie Arrius’ Buy rating, while his Street-high $700 price target suggests shares will climb as much as 33% in the coming months. (Click here to view Arias’ track record)

None of Arias’ co-workers have a problem with that take. All 9 recent reviews are positive, naturally making the consensus here a Strong Buy. According to the average target price of $643.89, the shares will give a return of ~21% in the coming year. (Look TMO Stock Forecast,

Taiwan Semiconductor (tsm,

For our next Griffin-approved name, we’ll shift our focus from one industry giant to another segment leader. Taiwan Semiconductor is a leading global semiconductor manufacturer. Since its inception in 1987, the company has emerged as a major player in the semiconductor industry, specializing in the production of advanced integrated circuit (IC) and system-on-chip (SoC) solutions. As the world’s largest dedicated semiconductor foundry, Taiwan Semiconductor is contracted by firms such as Apple, AMD, Nvidia and Qualcomm to manufacture chips. With such prominent clients, it is no surprise that this mega-cap company boasts a market capitalization of $450 billion.

That said, as is evident in other big tech companies, the global economic downturn has affected TSM as well. In the most recent quarterly report, the company made a mixed statement. Citing “softening end-market demand,” revenue declined 4.8% year-over-year to $16.72 billion, missing consensus estimates in turn by $170 million. However, earnings per share of $1.31 beat forecasts of $1.20.

For the second quarter, revenue is forecast to be between $15.2 and $16 billion, down from the $18.16 billion generated in the same period a year earlier, although the company said that by Q3, it expects inventory to be “more healthy”. But will come back. level.”

Meanwhile, Griffin isn’t going anywhere. The billionaire has a sizeable TSM position with an ownership of 25,228,676 shares. These currently command a market value of $2.33 billion.

For Susquehanna analyst Mehdi Hosseini, it’s clear where TSM’s value proposition lies. The 5-star analyst explained, “In our view, TSM remains the preferred foundry choice for leading edge nodes as Samsung Foundry has yet to demonstrate a stable leading edge process technology, while IFS has failed to offer competitive solutions.” years away.” , “It is no wonder that large customers rely on TSM as a single source foundry partner. Given the leverage inherent in TSM’s business model, we argue that the risk/reward profile is favorable as a quarterly EPS bottom in 2Q23, followed by a rebound in 2H23 and gaining momentum in 2024.

Accordingly, Hosseini rates TSM shares as a Positive (i.e., Buy) and supports the rating with a $126 price target. Implications for investors? Potential upside of 36% from current levels. (Click here to view Hussaini’s track record)

Three other analysts have recently stepped in with TSM reviews, and they’re all singing the company’s praises, assigning the stock a Strong Buy consensus rating. The forecast calls for one-year gains of 29%, considering the average target is $118.67. (Look tsm stock forecast,

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all of TipRank’s equity insights.

Disclaimer: The views expressed in this article are those of select analysts only. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Source